Strona główna・Stock List・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Closed

SectorHealthcare

31.59 3.68

Buy Sell

Overview

Share price change

24h

Current

Min

29.15

Max

30.85

Key metrics
By Trading Economics
Income	8.9M -99M
Sales	779K 21M
EPS	-1.69
Profit margin	-477.735
Employees	539
EBITDA	23M -98M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+34.25% upside

Dividends
By Acuity
Next Earnings	29 paź 2026

Market Stats
By TradingEconomics
Market Cap	746M 2.2B
Previous open	27.91
Previous close	31.59

News Sentiment

By Acuity

50%

151 / 340 Ranking in Healthcare

Agios Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 lip 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 lip 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 lip 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 lip 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 lip 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 lip 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 lip 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 lip 2026, 19:01 UTC

News

Event

Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Peer Comparison

Price change

Agios Pharmaceuticals Inc Forecast

Price Target

By TipRanks

34.25% upside

12 Months Forecast

Average 41 USD 34.25%

High 55 USD

Low 31 USD

Based on 9 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Agios Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.